LIFE SCIENCE LIVE 2019
Artificial Intelligence & Health –
May 15–16, Turku Fair and Congress Center
Life Science Live consists of three parallel seminars:
The HealthBIO event organized since 2007 has become the biggest annual Finnish health-biotech company meeting. The event offers you an opportunity to meet big international Life Science companies, SMEs and rising stars at 1-to-1 meetings. With altogether ca. 200 – 250 attendees, the main health-biotech company decision makers in Finland join the event for partnering and presentations. This is the event to make contacts in Finland.
The program – in English – covers highlights of the recent industry milestones and prospects for the future in Finland and Europe with international speakers as well as funding trends and success stories of fast-growing SMEs. The day ends with an informal get-together event.
Next day a partnering event organized in collaboration with European Enterprise Network EEN enables you to get more business contacts. The partnering day, that also includes a pitching competition, is hosted by Business Finland, which selects the presentation topics for the competition.
You will be able to listen to start-up pitches and get cutting-edge information about the academic research and co-development opportunities as well as learn about the results from different research groups. More information on how to apply to pitch will be published later.
PLEASE NOTE: Separate registration to face-to-face meetings on Partnering Day at healthbio-2019-partnering-day.b2match.io
The Science Track
The two sessions of the Science Track have been entitled “Intelligent Solutions for Health” and “Personalized Health”. The programme committee has invited internationally known experts representing academic research, enterprises and public agencies to cover these timely topics. The University of Turku and the Åbo Akademi University will also build a large exhibition that introduces e.g. the latest research projects and innovations, life science technology platforms and biobanking.
i~HD Conference – Maximising the Value of
Health Data to All
The European Institute for Innovation through Health Data (i~HD) is a not for profit institute legally registered in Belgium. It is a membership-based organisation with members from pharma, healthcare providers, academic organisations, and also works closely with patient organisations, healthcare payers, the health ICT sector and standards development organisations.
The vision of i~HD is to improve healthcare and to accelerate research through more trustworthy learning from health data. i~HD has specialist expertise in information governance, privacy protection (including GDPR compliance) and information security, in particular regarding the reuse of health data in research under a variety of legal bases.
It runs a Network of Excellence of European hospitals who are keen to accelerate their reuse of health data to improve outcomes and to participate more extensively in research including pharma sponsored clinical trials.
i~HD has developed methods and tools to assess and help improve the quality of EHR data. It promotes the importance of data quality for the benefit of learning health systems, patient empowerment and clinical research. It has led or co-led the development of ISO standards on EHR interoperability, consent and confidentiality, contributed to HL7 standards on clinical data, served on the Board of CDISC and been part of many European think tanks and investigations into interoperability issues. Read more about our event in Turku: www.i-hd.eu
Plenary. IBM: Andrew Fried, IBM Global Life Sciences Industry Leader
10.30 Opening words by the Chair of the day. Jari Forsström, Abomics Oy and Healthtech Finland, Genomic Industry SIG
10.45 Finnish biotech year 2018. Tero Piispanen, HealthTurku, Turku Science Park Oy
11.15 Are there any more traditional Venture Capitalists? Walter Stockinger, Hadean Ventures
Part One of Session One
Professor Moncef Grabbouj, University of Tampere
Professor Martin Cowie, Imperial College London
The Health data landscape, Professor Dipak Kalra, President of i~HD
The hospital perspective, Professor Juuso Bloomster, University of Turku
The pharma industry perspective, Bart Vannieuwenhuyse, Jannsen
The patient perspective,Pieter van Galen, Belgium, Patient representative
Kristoffer Miving, Digital lead, Nordics & Baltics, Janssen
Tommi Lehtonen, CEO, Blueprint Genetics Oy
Karen Madden, VP Technology and Innovation,PerkinElmer Inc.
Part Two of Session One
Jason Swedlow, University of Dundee
Other speaker TBC
Measuring and improving data quality in hospitals:
Professor Pascal Coorevits, i~HD and University of Gent
Frank Staelens, OLV Hospital Aalst, Belgium
Compying with the GDPR when reusing real world data for research:
Dr Nathan Lea, i~HD and University College London
Dr Filip De Meyer, i~HD and University of Gent
15.15 The New Modalities Ecosystem project ; what is there for me? Antti Haapalinna, Orion Pharma Ltd
15.40 How to explore the commercial potential of a life science idea? Giles Dudley, Senior Business Developer, BioInnovation Institute (Novo Foundation)
16.05 Ending discussion and an overview of the Personalised health program. Sampo Sammalisto, Business Finland
16.20 Ending discussion. Jari Forsström, Business Finland
Dipak Kalra, President of the European Institute for Innovation through Health Data
Part One of Session Two
Professor Olli Raitakari, University of Turku
Dr. Laura Elo, University of Turku
Opening remarks, Professor Dipak Kalra, President of i~HD
EHR2EDC, Nadir Ammour, Sanofi
EHDEN, Nigel Hughes, Janssen
Evidencing value based care through hospital EHRs and ICHOM standards, Thomas Allvin, EFPIA
Trillium II and the International Patient Summary, Dr Catherine Chronaki, HL7 Europe
Register for one-on-one partnering sessions
Digital Health Europe, Dr Veli Stroetmann, empirica
(further speaker details to be confirmed)
Part Two of Session Two
Dr. Antti Karlsson, Auria Biobank
Dr. Teemu Suna, Nightingale Health Ltd.
Dr. Päivi Ruokoniemi, FIMEA
Register for one-on-one partnering sessions